KineMed Announces Extension of Its Collaboration with Bristol-Myers Squibb

Backed by its pharma partner, Bristol-Myers Squibb, California-based KineMed is developing a disease biomarker based on its propriety technology to monitor neuronal transport dynamics. While KineMed’s current efforts target development of a biomarker for Alzheimer’s Disease, the technological progress made here will speed the translation of this technology for biomarker discovery in other neurodegenerative diseases including ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail